A detailed history of Great West Life Assurance CO transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 84,275 shares of VKTX stock, worth $3.56 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
84,275
Previous 82,416 2.26%
Holding current value
$3.56 Million
Previous $4.36 Million 22.47%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $92,652 - $131,003
1,859 Added 2.26%
84,275 $5.34 Million
Q2 2024

Aug 12, 2024

BUY
$47.39 - $80.2 $273,914 - $463,556
5,780 Added 7.54%
82,416 $4.36 Million
Q1 2024

May 13, 2024

BUY
$17.4 - $94.5 $1.18 Million - $6.41 Million
67,877 Added 774.94%
76,636 $6.3 Million
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $46,224 - $67,728
4,233 Added 93.53%
8,759 $97,000
Q2 2023

Aug 10, 2023

BUY
$14.84 - $24.79 $11,501 - $19,212
775 Added 20.66%
4,526 $74,000
Q1 2023

May 12, 2023

BUY
$8.08 - $17.33 $30,308 - $65,004
3,751 New
3,751 $63,000
Q2 2022

Aug 09, 2022

SELL
$2.11 - $3.15 $8,081 - $12,064
-3,830 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$5.73 - $8.11 $21,945 - $31,061
3,830 New
3,830 $22,000
Q3 2020

Nov 13, 2020

SELL
$5.73 - $8.11 $21,945 - $31,061
-3,830 Closed
0 $0
Q4 2019

Feb 11, 2020

BUY
$6.38 - $8.73 $24,435 - $33,435
3,830 New
3,830 $30,000
Q3 2019

Oct 25, 2019

SELL
$6.55 - $8.6 $47,284 - $62,083
-7,219 Closed
0 $0
Q4 2018

Feb 12, 2019

BUY
$7.16 - $16.21 $51,688 - $117,019
7,219 New
7,219 $53,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.24B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.